EP2928300A4 - Traitement de troubles du spectre autistique à l'aide de l'acide glycyl-l-2-méthylprolyl-l-glutamique - Google Patents
Traitement de troubles du spectre autistique à l'aide de l'acide glycyl-l-2-méthylprolyl-l-glutamiqueInfo
- Publication number
- EP2928300A4 EP2928300A4 EP13858943.7A EP13858943A EP2928300A4 EP 2928300 A4 EP2928300 A4 EP 2928300A4 EP 13858943 A EP13858943 A EP 13858943A EP 2928300 A4 EP2928300 A4 EP 2928300A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- methylprolyl
- glycyl
- treatment
- glutamic acid
- autism spectrum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261730829P | 2012-11-28 | 2012-11-28 | |
PCT/US2013/072049 WO2014085480A1 (fr) | 2012-11-28 | 2013-11-26 | Traitement de troubles du spectre autistique à l'aide de l'acide glycyl-l-2-méthylprolyl-l-glutamique |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2928300A1 EP2928300A1 (fr) | 2015-10-14 |
EP2928300A4 true EP2928300A4 (fr) | 2016-07-13 |
Family
ID=50828422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13858943.7A Withdrawn EP2928300A4 (fr) | 2012-11-28 | 2013-11-26 | Traitement de troubles du spectre autistique à l'aide de l'acide glycyl-l-2-méthylprolyl-l-glutamique |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2928300A4 (fr) |
JP (1) | JP2016506380A (fr) |
AU (1) | AU2013352294A1 (fr) |
BR (1) | BR112015012506A2 (fr) |
CA (1) | CA2929286A1 (fr) |
WO (1) | WO2014085480A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016004111A1 (fr) * | 2014-06-30 | 2016-01-07 | Cerora, Inc. | Système et procédés de synchronisation d'un pc à système d'exploitation non en temps réel avec un microcontrôleur de collecte de données à distance en temps réel |
EP4356964A3 (fr) * | 2018-08-10 | 2024-06-19 | New York University | Utilisation de ligands agonistes du récepteur de l'igf-2 pour le traitement du syndrome d'angelman et de l'autisme |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002094856A2 (fr) * | 2001-05-24 | 2002-11-28 | Neuronz Limited | Peptidomimetiques et analogues de gpe |
US20110112033A1 (en) * | 2001-05-24 | 2011-05-12 | Peter David Gluckman | Cognitive enhancement and cognitive therapy using glycyl-l-2-methylprolyl-l-glutamic acid |
WO2011146109A2 (fr) * | 2010-05-17 | 2011-11-24 | Mount Sinai School Of Medicine | Procédés et tests pour le traitement de sujets présentant une délétion, une mutation ou une expression réduite de shank3 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006127702A2 (fr) * | 2005-05-23 | 2006-11-30 | Neuren Pharmaceuticals Limited | Analogues de glycyl-prolyl-glutamate |
EP1793671B1 (fr) * | 2004-09-20 | 2011-04-27 | Mount Sinai School of Medicine | Utilisation de memantine (namenda) pour traiter l'autisme, les etats compulsifs et impulsifs |
ES2487493T3 (es) * | 2006-03-14 | 2014-08-21 | Neuren Pharmaceuticals Limited | Formulaciones orales de glicil-2-metilprolil-glutamato |
WO2008066750A1 (fr) * | 2006-11-22 | 2008-06-05 | Seaside Therapeutics, Llc | Procédés de traitement du retard mental, du syndrome de down, du syndrome de l'x fragile et de l'autisme |
CA2689549A1 (fr) * | 2007-06-08 | 2008-12-18 | Massachusetts Institute Of Technology | Traitement du syndrome de rett et d'autres troubles |
JP6348283B2 (ja) * | 2011-01-27 | 2018-06-27 | ニューレン ファーマシューティカルズ リミテッド | グリシル−l−2−メチルプロリル−l−グルタミン酸を用いる自閉症スペクトラム障害の治療 |
-
2013
- 2013-11-26 JP JP2015545191A patent/JP2016506380A/ja active Pending
- 2013-11-26 BR BR112015012506A patent/BR112015012506A2/pt not_active Application Discontinuation
- 2013-11-26 EP EP13858943.7A patent/EP2928300A4/fr not_active Withdrawn
- 2013-11-26 AU AU2013352294A patent/AU2013352294A1/en not_active Abandoned
- 2013-11-26 WO PCT/US2013/072049 patent/WO2014085480A1/fr active Application Filing
- 2013-11-26 CA CA2929286A patent/CA2929286A1/fr not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002094856A2 (fr) * | 2001-05-24 | 2002-11-28 | Neuronz Limited | Peptidomimetiques et analogues de gpe |
US20110112033A1 (en) * | 2001-05-24 | 2011-05-12 | Peter David Gluckman | Cognitive enhancement and cognitive therapy using glycyl-l-2-methylprolyl-l-glutamic acid |
WO2011146109A2 (fr) * | 2010-05-17 | 2011-11-24 | Mount Sinai School Of Medicine | Procédés et tests pour le traitement de sujets présentant une délétion, une mutation ou une expression réduite de shank3 |
Non-Patent Citations (3)
Title |
---|
ADRIAN BIRD: "The methyl-CpG-binding protein MeCP2 and neurological disease", BIOCHEMICAL SOCIETY TRANSACTIONS, vol. 36, no. 4, 1 August 2008 (2008-08-01), GB, pages 575 - 583, XP055276490, ISSN: 0300-5127, DOI: 10.1042/BST0360575 * |
See also references of WO2014085480A1 * |
WENLIN LIAO ET AL: "MeCP2+/ mouse model of RTT reproduces auditory phenotypes associated with Rett syndrome and replicate select EEG endophenotypes of autism spectrum disorder", NEUROBIOLOGY OF DISEASE, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 46, no. 1, 31 December 2011 (2011-12-31), pages 88 - 92, XP028467473, ISSN: 0969-9961, [retrieved on 20120109], DOI: 10.1016/J.NBD.2011.12.048 * |
Also Published As
Publication number | Publication date |
---|---|
EP2928300A1 (fr) | 2015-10-14 |
AU2013352294A1 (en) | 2015-07-09 |
CA2929286A1 (fr) | 2014-06-05 |
JP2016506380A (ja) | 2016-03-03 |
BR112015012506A2 (pt) | 2017-07-11 |
WO2014085480A1 (fr) | 2014-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI2667715T1 (sl) | Zdravljenje motenj avtističnega spektra z uporabo glicil-l-2-metilprolil-l-glutaminske kisline | |
HK1215375A1 (zh) | 阿克曼氏菌用於治療代謝病症的用途 | |
PL2919796T3 (pl) | Zastosowanie bakterii akkermansia w leczeniu zaburzeń metabolicznych | |
HK1207397A1 (en) | Purification of succinic acid | |
HK1211213A1 (en) | Treatment of diseases involving mucin | |
HK1204573A1 (en) | Treatment of inflammatory skin disorders | |
IL225896A0 (en) | Treatment of mecp-2 related disorders | |
EP2709665A4 (fr) | Traitement du psoriasis | |
HK1216504A1 (zh) | 疾病的治療方法 | |
EP2928300A4 (fr) | Traitement de troubles du spectre autistique à l'aide de l'acide glycyl-l-2-méthylprolyl-l-glutamique | |
IL234796B (en) | Compounds for the treatment of diseases related to ischemia-reperfusion | |
GB201218263D0 (en) | Treatment of autism | |
GB201201779D0 (en) | Treatment of inflammatory disorders | |
GB201221118D0 (en) | Methods of treatment | |
GB201216748D0 (en) | Methods of treatment | |
GB201216740D0 (en) | Methods of treatment | |
GB201206330D0 (en) | Methods of treatment | |
GB201206325D0 (en) | Methods of treatment | |
GB201206326D0 (en) | Methods of treatment | |
GB201206324D0 (en) | Methods of treatment | |
GB201204645D0 (en) | Treatment of disease | |
GB201221032D0 (en) | Method of treatment | |
GB201207359D0 (en) | Compounds for the treatment of metabolic disorders | |
GB201207363D0 (en) | Compounds for the treatment of metabolic disorders | |
GB201207894D0 (en) | Method of treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20150626 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20160609 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A01N 43/46 20060101AFI20160603BHEP Ipc: C07D 207/00 20060101ALI20160603BHEP Ipc: A61K 31/41 20060101ALI20160603BHEP Ipc: A61P 25/28 20060101ALI20160603BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20170110 |